Pioneering research suggests that the shingles vaccine could offer protection beyond preventing the painful viral infection, with the first global systematic review finding an 18% lower risk of stroke or heart attack in adults who receive the jab. The meta-analysis, which included 19 studies combining randomized controlled trials and observational research, indicates that vaccination may reduce cardiovascular events by curbing inflammation triggered by herpes zoster.
Adults aged 18 and older saw the largest benefits, with a slightly lower—but still significant—risk reduction for those over 50. Experts say the findings are promising but caution that further research is needed to confirm causation and understand the underlying mechanisms. The NHS has expanded eligibility for the vaccine from September, including younger adults with severely weakened immune systems, reflecting growing interest in the broader health benefits of vaccination.
